PMID: 8605901Oct 1, 1995Paper

Detection of aminoglycoside-penicillin synergy against Enterococcus faecium using high-content aminoglycoside disks

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
C TorresF Baquero

Abstract

Thirty-seven Enterococcus faecium strains were screened for high-level aminoglycoside resistance with an agar diffusion test using high-content aminoglycoside disks (300 micrograms of streptomycin and 120 micrograms of gentamicin, tobramycin, kanamycin or amikacin). The inhibition zones obtained were correlated with results of time-kill penicillin-aminoglycoside synergy studies. An 11 mm breakpoint differentiated strains susceptible or resistant to the synergy of streptomycin plus penicillin. Irrespective of the inhibition zones obtained with tobramycin and kanamycin disks, Enterococcus faecium strains never showed synergy with penicillin in combination with these aminoglycosides. Penicillin-amikacin synergy cannot be predicted by the amikacin disks. Nevertheless, even though kanamycin disks do not predict penicillin-kanamycin synergy, they can be used to predict penicillin-amikacin synergy. In summary, high-content streptomycin, gentamicin and kanamycin disks can be used to predict the susceptibility of Enterococcus faecium strains to the synergistic combination of penicillin plus one of the aminoglycosides (streptomycin, gentamicin or amikacin, respectively).

References

Aug 1, 1979·The Journal of Infectious Diseases·R C MoelleringC B Wennersten
Sep 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R LeclercqP Courvalin
Aug 1, 1990·Antimicrobial Agents and Chemotherapy·C Carlier, P Courvalin
Jan 1, 1990·Clinical Microbiology Reviews·B E Murray
Apr 1, 1989·Journal of Clinical Microbiology·R R Facklam, M D Collins
Oct 1, 1988·Antimicrobial Agents and Chemotherapy·G M EliopoulosR C Moellering
Aug 1, 1973·Antimicrobial Agents and Chemotherapy·C Watanakunakorn, C Bakie
Mar 1, 1971·Journal of Bacteriology·R A ZimmermannA N Weinberg
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·Y CostaP Courvalin
Nov 1, 1993·Antimicrobial Agents and Chemotherapy·C TorresF Baquero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.